Highest-materiality recent filing
AVITA Medical issues warrant to Perceptive for 500,000 shares at $3.4019 after shareholder approval
Stockholders approved warrant at June 3, 2026 Annual Meeting; warrant issued June 5.
AVITA Medical shareholders approve director fee pool increase, equity grants, and warrant issuance
Non-executive director cash fee pool increased from $750K to $900K per annum.
AVITA Medical Q1 revenue $19.3M (+4% YoY); net loss narrows to $10.6M
Total revenue $19.3M, up 4% YoY and 10% sequentially, driven by Cohealyx and improved RECELL utilization.
AVITA Medical appoints Cary Vance as permanent CEO, Jan Stern Reed as Board Chair
Cary Vance named President and CEO effective April 30, 2026; served as Interim CEO since October 2025.
AVITA Medical Q4 revenue down 4% to $17.6M; FY2026 guidance $80-85M
Q4 revenue $17.6M (down 4% YoY); gross margin 81.2% vs 87.6%; net loss $11.6M ($0.38/sh) vs $11.6M ($0.44/sh).
AVITA Medical: Q4 rev ~$17.6M, FY2025 $71.6M; new $60M credit facility; FY2026 guidance $80-85M
Q4 2025 revenue ~$17.6M (vs $18.4M Q4 2024); Cohealyx-I fully enrolled, PermeaDerm-I >75% enrolled in Dec 2025.
AVITA Medical appoints Joe Woody to board; Lou Panaccio retires
Joe Woody appointed non-executive director effective Jan 1, 2026; Lou Panaccio retires after 10+ years.
AVITA Medical Q3 revenue falls 13% YoY to $17.1M; lowers FY2025 revenue guidance to $70-74M
Net loss improved to $13.2M ($0.46 loss per share) from $16.2M in Q3 2024; cash use cut to $6.2M.
AVITA Medical CEO departs, interim CEO appointed; Q3 preliminary revenue ~$17M
CEO Jim Corbett departed Oct 16, 2025; Chairman Cary Vance appointed Interim CEO effective immediately.
AVITA Medical raises ~$15M via placement of 17.2M CDIs at AU$1.32 each
Issued 17.2M CHESS Depositary Interests (CDIs) at AU$1.32/CDI; 5 CDIs = 1 common share.
AVITA Medical raises US$15M via Australian private placement at A$1.32/CDI
Raised ~US$15M (~A$23M) by issuing ~17.2M new CDIs at A$1.32 each (11% discount to last ASX close).
Q2 2025 commercial revenue $18.4M (+21% YoY); net loss $9.9M vs $15.4M prior year.
AVITA Medical appoints Michael Tarnoff to Board; Cary Vance becomes Board Chair
Dr. Michael Tarnoff appointed as non-executive Director, effective August 6, 2025; most recently Chief Physician Executive and CEO at Tufts Medical Center.
AVITA Medical shareholders approve amended incentive plan, increase share reserve by 2.5M
Amended 2020 Omnibus Incentive Plan approved, increasing share reserve by 2.5M to 6.75M shares.
Bylaws amended and restated effective May 15, 2025, to reflect recent changes in applicable corporate law.
AVITA Medical Q1 revenue $18.5M (+67% YoY); reaffirms FY guidance $100-106M
Net loss of $13.9M ($0.53/sh) improved from $18.7M loss ($0.73/sh) in Q1 2024.
AVITA Medical to manufacture PermeaDerm; revenue share rises to 60%
10-year contract manufacturing agreement for PermeaDerm at AVITA's Ventura, CA facility.
AVITA Medical Q4 revenue $18.4M (+30% YoY), net loss $11.6M; FY2025 guidance $100-106M
Q4 commercial revenue $18.4M (+30% YoY); gross margin 87.6%.
AVITA Medical slashes Q4 2024 revenue outlook to ~$18.4M; profitability pushed to Q4 2025
Q4 2024 commercial revenue expected ~$18.4M (30% YoY growth) vs prior guidance of $22.3-24.3M.
AVITA Medical Q3 revenue $19.5M (+44% YoY); amends OrbiMed debt, removes $50M tranches
Commercial revenue $19.5M, up 44% YoY; gross margin 83.7% vs 84.5%.
AVITA Medical Q2 commercial revenue record $15.1M (+29%); FY24 guide $68-70M
Commercial revenue $15.1M (+29% YoY); gross margin 86.2% (up 500 bps).
Exclusive 5-year deal for collagen-based dermal matrix; Regenity expects 510(k) clearance in Q4 2024.
AVITA Medical appoints Nicole Kelsey as Chief Legal & Compliance Officer; Donna Shiroma retires
Donna Shiroma retired as General Counsel effective June 28, 2024, succeeded by Nicole Kelsey.
AVITA Medical shareholders elect directors, approve equity awards at annual meeting
All seven director nominees elected: Louis Panaccio, James Corbett, Jeremy Curnock Cook, Suzanne Crowe, Jan Stern Reed, Robert McNamara, Cary Vance.
AVITA Medical receives FDA approval for RECELL GO next-gen skin harvesting device
FDA approved RECELL GO next-gen autologous cell harvesting device for thermal burn wounds and full-thickness skin defects.
AVITA Medical Q1 revenue $11.1M (+5.8%), net loss $18.7M; lowers 2024 revenue guidance to lower end
Commercial revenue $11.1M, up 5.8% YoY; gross margin 86.4%.
AVITA Medical cuts Q1 2024 revenue guidance to $11.0-$11.3M from prior $14.8-$15.6M
Expected Q1 commercial revenue $11.0M-$11.3M vs prior guidance $14.8M-$15.6M.
AVITA Medical Q4 commercial revenue up 50% to $14.1M; guides FY2024 rev $78.5-84.5M
Commercial revenue Q4 $14.1M (+50% YoY); gross margin 87.3%.
AVITA reports preliminary FY2023 revenue $49.8M (+46% YoY), signs PermeaDerm distribution deal
Q4 2023 commercial revenue ~$14.1M (+50% YoY); full-year 2023 commercial revenue ~$49.8M (+46% YoY).
AVITA Medical Q3 commercial revenue up 51% to $13.5M; net loss $8.7M
Commercial revenue $13.5M (+51% YoY); total revenue $13.6M; gross margin 84.5%.
AVITA Medical settles $1M with former CEO Dr. Michael Perry over departure claims
Settlement of $1 million, split into wage and non-wage payments, for general release of claims.
AVITA Medical secures $90M debt facility from OrbiMed; prelim Q3 revenue $13.5M (+50% YoY)
Preliminary Q3 commercial revenue $13.5M, +50% YoY from ~$9.0M; gross margin ~84.5%.
AVITA Medical receives FDA additional info request for RECELL GO PMA; launch pushed to mid-2024
FDA placed RECELL GO PMA supplement on hold for ~4-6 months pending additional info.
Commercial revenue $11.7M (+42% YoY); net loss $0.41/share vs $0.25 loss in prior year.
AVITA Medical reveals ~391K annual eligible procedures after expanded RECELL FDA approval
Expanded FDA indication for full-thickness skin defects opens ~391,000 annual eligible procedures.
AVITA Medical names David O'Toole CFO; $450K salary, 150K options
David O'Toole appointed CFO effective June 15, 2023; brings 30+ years biotech/life sciences finance experience.
AVITA Medical stockholders approve 2.5M share increase in 2020 Omnibus Plan and new ESPP
Stockholders approved amendment to 2020 Omnibus Incentive Plan increasing shares by 2.5 million.
AVITA Medical corrects Q1 revenue to $10.6M, net loss $9.2M in 8-K/A amendment
Revenue $10.6M (U.S. Dollars); net loss $9.2M, $0.37 per share for quarter ended March 31, 2023.
AVITA Medical Q1 commercial revenue up 40% to $10.5M; reaffirms FY guidance; CCO resigns
Commercial revenue $10.5M (+40% YoY); total revenue $10.6M (+40%); gross margin 84% vs 76%.
AVITA Medical to report Q1 2023 financial results on May 11 after market close
Results will be released after U.S. markets close on Thursday, May 11, 2023.
AVITA Medical appoints Robert McNamara to board, sets 2023 annual meeting
Robert McNamara appointed to Board of Directors effective April 1, 2023.
Annual bonus payout moved to no later than March 15 for prior calendar year.
AVITA Medical appoints Cary Vance to Board of Directors, effective April 1, 2023
Cary Vance appointed as non-executive director, effective April 1, 2023, serving until 2023 Annual Meeting.
AVITA Medical CEO presented at TD Cowen Health Care Conference on March 7
CEO Jim Corbett presented at TD Cowen 43rd Annual Health Care Conference in Boston.
AVITA Medical holds Q4 2022 investor webinar; no new material information disclosed
Webinar held Feb 28, 2023 with CEO Jim Corbett and acting CFO Sean Ekins.
AVITA Medical to report Q4/FY2022 results on Feb 23, 2023, provide 2023 guidance
Results due after market close on Thursday, Feb 23, 2023.
CFO Michael Holder and COO Kathy McGee leaving Avita Medical effective Jan 19, 2023.
AVITA Medical submits FDA PMA application for RECELL System to treat stable vitiligo
PMA submitted to FDA to expand RECELL indication to stable vitiligo; received Breakthrough Device designation.
Avita Medical annual meeting: all directors elected, quorum bylaw amendment fails
All five director nominees elected; each received 9.2M-10.4M votes for.
AVITA Medical Q3 commercial rev $9.0M, up 30%; raises FY guidance; pivotal trial endpoints met
Commercial revenue (ex-BARDA) $9.0M, +30% YoY; total revenue $9.1M.
the Board appointed Jan Stern Reed as Chair of the Board while simultaneously terminating the Lead Independent Director position that she had been serving since October 2025
the Board of Directors (the “Board”) of AVITA Medical, Inc (the "Company") appointed Cary Vance as President and Chief Executive Officer ("CEO"), effective April 30, 2026
On June 28, 2024, Ms. Donna Shiroma, the Company’s General Counsel, Compliance Officer and Corporate Secretary, notified AVITA Medical, Inc. (the "Company") of her retirement effective immediately.
Ms. Shiroma is succeeded by Nicole Kelsey, effective immediately, who will serve as the Company’s Chief Legal and Compliance Officer and Corporate Secretary.
AVITA Medical, Inc. (the “Company”) entered into an Executive Employment Agreement (the “Agreement”) with David O’Toole with an effective date of June 15, 2023 (the “Effective Date”), pursuant to which Mr. O’Toole will serve as the Company’s Chief Financial Officer.
Effective May 11, 2023, Ms. Erin Liberto, the Company’s Chief Commercial Officer, resigned from her position and accepted a role with a privately held, non-competitive business.
On March 23, 2023, AVITA Medical, Inc. (the “Company”) issued a press release announcing the appointment of Robert McNamara to its Board of Directors (the “Board”), effective April 1, 2023
On March 16, 2023, AVITA Medical, Inc. (the “Company”) issued a press release announcing the appointment of Cary Vance to its Board of Directors (the “Board”), effective April 1, 2023
Michael Holder, the Company’s Chief Financial Officer, and Kathy McGee, the Company’s Chief Operating Officer, are leaving the organization.
Mr. Holder’s responsibilities as the Company’s principal financial officer and principal accounting officer will transition to Mr. Sean Ekins, as Interim Chief Financial Officer, effective immediately.
Effective September 28, 2022, the Board of Directors of the Company appointed James Corbett as the Company’s President and CEO.
Effective September 28, 2022, the Board of Directors of Avita Medical, Inc. (the “Company”) terminated the employment of Dr. Michael Perry, the Company’s President and CEO.
Max materiality 0.85 · Median 0.65 · Most common event earnings